方盛制药:2024年报净利润2.55亿 同比增长36.36%

Financial Performance - The basic earnings per share for 2024 is 0.5900 yuan, an increase of 37.21% compared to 0.4300 yuan in 2023 [1] - The net profit for 2024 is 2.55 billion yuan, reflecting a growth of 36.36% from 1.87 billion yuan in 2023 [1] - The return on equity for 2024 stands at 16.60%, up 31.96% from 12.58% in 2023 [1] - The total revenue for 2024 is 17.77 billion yuan, a 9.09% increase from 16.29 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 21,148.53 million shares, accounting for 48.2% of the circulating shares, which is a decrease of 763.34 million shares from the previous period [1] - Zhang Qinghua remains the largest shareholder with 15,601.95 million shares, representing 35.56% of the total share capital, unchanged from the previous report [2] - The E Fund Healthcare Industry Mixed A fund has decreased its holdings by 588.07 million shares [2] Dividend Distribution - No specific details on the dividend distribution plan are provided in the documents [1][2]